White Papers

31. How AI Is Reshaping Trial Design, Execution, And Disclosure 9/25/2025

    AI has quietly embedded itself into the operational heart of clinical development, where it is accelerating decisions, reducing manual burden, and improving outcomes.

32. Decentralized And Community-Based Solutions Driving Women's Healthcare 9/24/2025

    Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.

33. Achieving End-To-End Clinical Supply Chain Visibility 9/23/2025

    Transform supply chain management by integrating technology solutions and real-time insights to link patient-level data with upstream manufacturing operations.

34. A Guide To Streamlining Study Start-Up In Australia 9/23/2025

    Discover the benefits of Australia as a premier destination for multinational sponsors looking to expedite drug development, refine trial design, and establish long-term research partnerships.

35. The Hidden Problem In Early Phase Oncology Trials 9/23/2025

    Integrating patient-reported outcome measures (PROMs) can enable improved capture tolerability and optimize dosing decisions.

36. A New Blueprint For Transforming Feasibility And Recruitment 9/22/2025

    Discover how a connected approach links feasibility and recruitment, using real-world data to design realistic protocols, reach the right patients, and accelerate enrollment with confidence.

37. Phase 1 Clinical Trial Designs And Strategies 9/18/2025

    With tailored guidance, sponsors can align their modern model-based and model-assisted design choices to program goals, accelerating progress while safeguarding patients.

38. Everest Group Life Sciences eCOA Peak Matrix Assessment 2025 9/16/2025

    Discover how digital platforms are revolutionizing clinical trials by improving data quality and patient engagement in this comprehensive market assessment.

39. Advancing Alzheimer's Disease Therapies 9/3/2025

    By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.

40. De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital 9/3/2025

    For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.